BR0208627A - Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila - Google Patents

Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila

Info

Publication number
BR0208627A
BR0208627A BR0208627-1A BR0208627A BR0208627A BR 0208627 A BR0208627 A BR 0208627A BR 0208627 A BR0208627 A BR 0208627A BR 0208627 A BR0208627 A BR 0208627A
Authority
BR
Brazil
Prior art keywords
fluorouracil
gemcitabine
rapamycin
antineoplastic combinations
antineoplastic
Prior art date
Application number
BR0208627-1A
Other languages
English (en)
Inventor
James Joseph Gibbons Jr
Gary Dukart
Jurgen Hermann Ernst Frisch
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0208627A publication Critical patent/BR0208627A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçõES ANTINEOPLáSICAS TAL COMO RAPAMICINA JUNTO COM GENCITABINA OU FLUOROURACILA". A invenção fornece o uso de uma combinação de um inibidor da mTOR tal como uma rapamicina e de um agente antineoplásico antimetabólito tal como a gencitabina ou a fluorouracila no tratamento de neoplasmas.
BR0208627-1A 2001-04-06 2002-04-05 Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila BR0208627A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28238501P 2001-04-06 2001-04-06
US28238801P 2001-04-06 2001-04-06
PCT/US2002/010912 WO2002080975A1 (en) 2001-04-06 2002-04-05 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil

Publications (1)

Publication Number Publication Date
BR0208627A true BR0208627A (pt) 2004-03-09

Family

ID=26961412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208627-1A BR0208627A (pt) 2001-04-06 2002-04-05 Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila

Country Status (22)

Country Link
EP (1) EP1385551B1 (pt)
JP (1) JP2004525950A (pt)
KR (1) KR100862178B1 (pt)
CN (1) CN1309421C (pt)
AT (1) ATE406892T1 (pt)
AU (1) AU2007242958A1 (pt)
BR (1) BR0208627A (pt)
CA (1) CA2442849A1 (pt)
DE (1) DE60228699D1 (pt)
EA (1) EA010184B1 (pt)
ES (1) ES2312568T3 (pt)
HK (1) HK1060062A1 (pt)
HU (1) HUP0304093A3 (pt)
IL (1) IL157898A0 (pt)
MX (1) MXPA03009092A (pt)
NO (1) NO20034433L (pt)
NZ (1) NZ540047A (pt)
PL (1) PL363991A1 (pt)
PT (1) PT1385551E (pt)
SG (1) SG152906A1 (pt)
SI (1) SI1385551T1 (pt)
WO (1) WO2002080975A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399766T1 (de) 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
NZ527692A (en) * 2001-02-19 2005-05-27 Novartis Ag Cancer treatment
GB0124577D0 (en) * 2001-10-12 2001-12-05 Novartis Forschungsstiftung Novel methods
CN100522967C (zh) 2002-02-01 2009-08-05 阿里亚德基因治疗公司 含磷化合物及其应用
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
JP2007525507A (ja) * 2004-02-26 2007-09-06 ザ ペン ステイト リサーチ ファンデーション オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法
WO2006027545A2 (en) * 2004-09-10 2006-03-16 Agency For Science, Technology And Research Method
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
EP3488866A1 (en) * 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2629714A1 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
ES2481671T3 (es) * 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
EP1976530A1 (en) * 2006-01-12 2008-10-08 Novartis AG Combination of mtor inhibitor and antipolate compound
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
US20090311249A1 (en) * 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
EP2054061A4 (en) * 2006-08-02 2009-09-02 Ariad Pharma Inc COMBINATION THERAPY
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
EP2087113A2 (en) * 2006-10-11 2009-08-12 Fusion Antibodies Limited Combination therapy
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
CA2675736A1 (en) 2007-01-19 2008-07-24 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
HUE039497T2 (hu) * 2007-03-07 2019-01-28 Abraxis Bioscience Llc Rapamicin rákellenes szert és albumint tartalmazó nanorészecske
PT2155188E (pt) 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
RU2492860C2 (ru) 2008-06-17 2013-09-20 УАЙТ ЭлЭлСи Антиопластические комбинации, содержащие нкi-272 и винорелбин
PL3175853T3 (pl) 2008-08-04 2024-03-25 Wyeth Llc Przeciwnowotworowe połączenia neratynibu i kapecytabiny
PL3000467T3 (pl) 2009-04-06 2023-05-02 Wyeth Llc Schemat leczenia wykorzystujący neratynib dla raka sutka
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
KR20170122734A (ko) 2015-02-25 2017-11-06 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
RS65129B1 (sr) 2016-03-28 2024-02-29 Incyte Corp Jedinjenja pirolotriazina kao inhibitori tam
WO2020006408A1 (en) 2018-06-29 2020-01-02 Incyte Corporation Formulations of an axl/mer inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6384019B1 (en) * 1997-01-24 2002-05-07 Norsk Hydro Asa Gemcitabine derivatives
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
HUP0304093A3 (en) 2008-08-28
HK1060062A1 (en) 2004-07-30
EA010184B1 (ru) 2008-06-30
NO20034433L (no) 2003-11-25
NZ540047A (en) 2007-01-26
EA200301091A1 (ru) 2004-02-26
SG152906A1 (en) 2009-06-29
PT1385551E (pt) 2008-11-03
ATE406892T1 (de) 2008-09-15
EP1385551A1 (en) 2004-02-04
KR20040007491A (ko) 2004-01-24
DE60228699D1 (de) 2008-10-16
MXPA03009092A (es) 2004-02-12
HUP0304093A2 (hu) 2004-04-28
CN1309421C (zh) 2007-04-11
CA2442849A1 (en) 2002-10-17
NO20034433D0 (no) 2003-10-03
IL157898A0 (en) 2004-03-28
KR100862178B1 (ko) 2008-10-09
EP1385551B1 (en) 2008-09-03
WO2002080975A1 (en) 2002-10-17
CN1545419A (zh) 2004-11-10
SI1385551T1 (sl) 2008-12-31
JP2004525950A (ja) 2004-08-26
AU2007242958A1 (en) 2008-01-10
PL363991A1 (en) 2004-11-29
ES2312568T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
BR0208627A (pt) Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila
BR0211769A (pt) Combinações antineoplásicas
CY2008014I2 (el) Β-αμινο-τετραϋδροϊμιδαζο-(1,2-α)-πυραζινες και τετραϋδροτριαζολο-(4,3-α)-πυραζινες ως αναστολεις της διπεπτιδυλο πεπτιδασης για την αγωγη ή προληψη του διαβητη
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
DE60206512D1 (de) Rapanycin29-enole
MXPA03001789A (es) Composiciones para el cuidado de telas que comprenden silicones cationicos y metodos que emplean las mismas.
ECSP056001A (es) Combinaciones antineoplásicas
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
DE50306232D1 (de) Ampholytisches copolymer und dessen verwendung
SV2005002048A (es) " combinaciones antineoplasticas de cci - 779 y rituximab " ref. am - 101608salvo
BR0104749A (pt) Taxanos substituìdos com éster em c7 comoagentes antitumor
ATE300306T1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
BRPI0415779A (pt) tratamento de doenças proliferativas usando um oligÈmero antisenso iap e um agente quimioterápico
ITBO970064A0 (it) Uso della rifaximina e delle composizioni farmaceutiche che la conteng ono nel trattamento della diarrea da criptosporidiosi.
ATE231872T1 (de) Thiazolopyrimidinderivate
BRPI0409632A (pt) combinações antineoplásticas
BR0210101A (pt) Combinações antineoplásticas
HUP0300848A2 (hu) Kamptotecint és egy pirimidinszármazékot tartalmazó készítmény rák kezelésére
ECSP034790A (es) Combinaciones antineoplásticas tales como rapamicin junto con gemcitabina o fluorouracil
BRPI0508795A (pt) composição de tratamento capilar, uso da composição, método de tratamento de cabelos e método de fabricação de composição de tratamento capilar
ECSP034866A (es) Combinaciones antineoplásticas
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
BR0008139B1 (pt) composição lubrificante, e, uso de uma composição lubrificante.
BR0210632A (pt) Tratamento de doença parasìtica
BR0315701B1 (pt) composiÇço, composiÇço de tratamento na lavagem de roupas, e, uso de uma composiÇço.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.